{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(5)"],"submitter":["Damiani V"],"pubmed_abstract":["Antibodies against the SARS-CoV-2 nucleocapsid protein are produced by the immune system in response to SARS-CoV-2 infection, but most available vaccines developed to fight the pandemic spread target the SARS-CoV-2 spike protein. The aim of this study was to improve the detection of antibodies against the SARS-CoV-2 nucleocapsid by providing a simple and robust method applicable to a large population. For this purpose, we developed a DELFIA immunoassay on dried blood spots (DBSs) by converting a commercially available IVD ELISA assay. A total of forty-seven paired plasma and dried blood spots were collected from vaccinated and/or previously SARS-CoV-2-infected subjects. The DBS-DELFIA resulted in a wider dynamic range and higher sensitivity for detecting antibodies against the SARS-CoV-2 n"],"journal":["Diagnostics (Basel, Switzerland)"],"pagination":["897"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10000641"],"repository":["biostudies-literature"],"pubmed_title":["Development of a Method for Detection of SARS-CoV-2 Nucleocapsid Antibodies on Dried Blood Spot by DELFIA Immunoassay."],"pmcid":["PMC10000641"],"pubmed_authors":["Demattia G","Cicalini I","Di Marzio C","Zucchelli M","Natale L","Damiani V","Pizzinato E","Federici L","De Laurenzi V","Pieragostino D","Palmarini C"],"additional_accession":[]},"is_claimable":false,"name":"Development of a Method for Detection of SARS-CoV-2 Nucleocapsid Antibodies on Dried Blood Spot by DELFIA Immunoassay.","description":"Antibodies against the SARS-CoV-2 nucleocapsid protein are produced by the immune system in response to SARS-CoV-2 infection, but most available vaccines developed to fight the pandemic spread target the SARS-CoV-2 spike protein. The aim of this study was to improve the detection of antibodies against the SARS-CoV-2 nucleocapsid by providing a simple and robust method applicable to a large population. For this purpose, we developed a DELFIA immunoassay on dried blood spots (DBSs) by converting a commercially available IVD ELISA assay. A total of forty-seven paired plasma and dried blood spots were collected from vaccinated and/or previously SARS-CoV-2-infected subjects. The DBS-DELFIA resulted in a wider dynamic range and higher sensitivity for detecting antibodies against the SARS-CoV-2 n","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-22T14:44:49.129Z","creation":"2025-02-19T02:41:22.949Z"},"accession":"S-EPMC10000641","cross_references":{"pubmed":["36900041"],"doi":["10.3390/diagnostics13050897"]}}